UPDATE: Goldman Sachs Maintains Neutral Rating on ViroPharma, Lowers PT


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Goldman Sachs reduced their Viropharma (NASDAQ: VPHM) estimates following a release of generic versions of their drug Vanco. Goldman Sachs went on to say, “…we are reducing our VPHM estimates for 2012-2015. This drives a decrease in our 12-month price target, equally based on our DCF/SOTP analyses, to $22 from $26.” VPHM closed yesterday at $22.44.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorReiterationAnalyst RatingsGoldman Sachs